サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1542614

ブルセラ病ワクチンの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

Global Brucellosis Vaccines Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 223 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
ブルセラ病ワクチンの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測
出版日: 2024年07月01日
発行: Value Market Research
ページ情報: 英文 223 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ブルセラ病ワクチン市場の世界需要は、2023年の2億7,938万米ドルから2032年には4億4,128万米ドルの市場規模に達し、調査期間2024～2032年のCAGRは5.21%に達すると推定されます。

ブルセラ病は、マルタ熱、ウンデュラント熱、地中海熱としても知られ、感染した動物の加熱不十分な肉、未殺菌牛乳の摂取、またはその分泌物との密接な接触によって引き起こされる感染症です。ブルセラ病ワクチンはウシ、ヒツジ、ヤギ用です。現在のところ、ヒト用のワクチンはありません。ワクチン接種は、動物の病気に対する抵抗力を高める免疫反応を作り出すことによって機能し、ブルセラ症を制御、管理、排除するために重要です。

市場力学

家畜生産の増加と動物を媒介とする感染症の脅威が市場の成長を牽引しています。畜産セクターの継続的な成長と変革に伴い、食糧安全保障と人間の栄養に関連した大きな課題が提供されています。畜産物の需要は、牛乳、肉、卵の消費量の増加に影響されて伸びています。世界的には、ブルセラ症は最も一般的な人獣共通感染症と考えられており、年間50万件以上の症例が記録されています。市場の成長はワクチン接種プログラムによって支えられています。その一方で、効果的な診断や治療ができない地域や、ヒトや動物への感染の検出や予防のためのプログラムが十分に実施されていない地域も多く存在します。このような地域では、ブルセラ症の予防と制御に役立てるため、政府の獣医部門と保健部門の連携と協力が必要です。

この調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、ブルセラ病ワクチンの世界市場における各セグメントを包括的に評価することもできます。ブルセラ病ワクチン産業の成長と動向は、この調査に全体的なアプローチを記載しています。

市場セグメンテーション

市場セグメンテーションでは、国別と地域別のセグメントに関する詳細なデータを提供し、各製品サービスの対象層と今後のビジネス機会を特定します。

地域分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおけるブルセラ病ワクチン市場の現在と将来の需要を強調する地域展望をカバーしています。さらに、このレポートでは、すべての主要地域における個々の用途セグメントの需要、推定・予測に焦点を当てています。

ご要望がございましたら、弊社までご連絡ください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 ブルセラ病ワクチン-産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカー一覧
    • 主要原材料の価格動向
  • 潜在的バイヤー一覧
  • マーケティングチャネル
    • 直接マーケティング
    • 間接マーケティング
    • マーケティングチャネル発展動向

第5章 ブルセラ病ワクチンの世界市場分析：タイプ別

  • タイプ別概要
  • タイプ別過去・予測データ分析
  • サブユニットワクチン（組み換えワクチン,混合ワクチン,トキソイドワクチン）
  • 不活化ワクチン
  • 生ワクチン
  • mRNAワクチン
  • ウイルスベクターワクチン

第6章 ブルセラ病ワクチンの世界市場分析：投与経路別

  • 投与経路別概要
  • 投与経路別過去・予測データ分析
  • 経口
  • 非経口
  • 経鼻

第7章 ブルセラ病ワクチンの世界市場分析：適応疾患別

  • 適応疾患別概要
  • 適応疾患別過去・予測データ分析
  • ウイルス性疾患（肝炎、インフルエンザ、HPV、MMR、ロタウイルス、帯状疱疹、COVID-19、その他）
  • 細菌ワクチン（髄膜炎菌感染症、肺炎球菌感染症、DPT、その他）
  • がんワクチン
  • アレルギー・ワクチン

第8章 ブルセラ症ワクチンの世界市場分析：年齢層別

  • 年齢層別概要
  • 年齢層別過去・予測データ分析
  • 小児
  • 成人

第9章 ブルセラ症ワクチンの世界市場分析：流通チャネル別

  • 流通チャネル別概要
  • 流通チャネル別過去・予測データ分析
  • 病院・小売薬局
  • 政府系サプライヤー
  • その他

第10章 ブルセラ病ワクチンの世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第11章 ブルセラ病ワクチン企業の競合情勢

  • ブルセラ病ワクチン市場競合
  • パートナーシップ/提携/協定
  • 合併・買収
  • 新製品発売
  • その他の開発

第12章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Merck & Co. Inc.
  • Laboratories Tornel
  • Hester Biosciences Limited
  • Ceva
  • CZ Vaccines
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Type (USD MN)
  • Subunit Vaccines (Recombinant Vaccines, Conjugate Vaccines, Toxoid Vaccines) Market Sales By Geography (USD MN)
  • Inactivated Market Sales By Geography (USD MN)
  • Live Attenuated Market Sales By Geography (USD MN)
  • mRNA Aaccines Market Sales By Geography (USD MN)
  • Viral Vector Vaccines Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Parenteral Market Sales By Geography (USD MN)
  • Nasal Market Sales By Geography (USD MN)
  • Analysis By Disease Indication (USD MN)
  • Viral Diseases (Hepatitis, Influenza, HPV, MMR, Rotavirus, Herpes Zoster, Covid-19, Others) Market Sales By Geography (USD MN)
  • Bacterial Vaccines (Meningococcal Diseases, Pneumococcal Diseases, DPT, Others) Market Sales By Geography (USD MN)
  • Cancer Vaccines Market Sales By Geography (USD MN)
  • Allergy Vaccines Market Sales By Geography (USD MN)
  • Analysis By Age (USD MN)
  • Pediatric Market Sales By Geography (USD MN)
  • Adult Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital & Retail Pharmacies Market Sales By Geography (USD MN)
  • Government Suppliers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Brucellosis Vaccines Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Brucellosis Vaccines Report
  • Market Research Process
  • Market Research Methodology
  • Global Brucellosis Vaccines Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Type
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By Disease Indication
  • Market Attractiveness Analysis By Age
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Type (USD MN)
  • Subunit Vaccines (Recombinant Vaccines, Conjugate Vaccines, Toxoid Vaccines) Market Sales By Geography (USD MN)
  • Inactivated Market Sales By Geography (USD MN)
  • Live Attenuated Market Sales By Geography (USD MN)
  • mRNA Aaccines Market Sales By Geography (USD MN)
  • Viral Vector Vaccines Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Parenteral Market Sales By Geography (USD MN)
  • Nasal Market Sales By Geography (USD MN)
  • Global Market Analysis By Disease Indication (USD MN)
  • Viral Diseases (Hepatitis, Influenza, HPV, MMR, Rotavirus, Herpes Zoster, Covid-19, Others) Market Sales By Geography (USD MN)
  • Bacterial Vaccines (Meningococcal Diseases, Pneumococcal Diseases, DPT, Others) Market Sales By Geography (USD MN)
  • Cancer Vaccines Market Sales By Geography (USD MN)
  • Allergy Vaccines Market Sales By Geography (USD MN)
  • Global Market Analysis By Age (USD MN)
  • Pediatric Market Sales By Geography (USD MN)
  • Adult Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital & Retail Pharmacies Market Sales By Geography (USD MN)
  • Government Suppliers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11212417

The global demand for Brucellosis Vaccines Market is presumed to reach the market size of nearly USD 441.28 Million by 2032 from USD 279.38 Million in 2023 with a CAGR of 5.21% under the study period 2024-2032.

Brucellosis also is known as malta fever, undulant fever, Mediterranean fever, is an infection caused by undercooked meat of infected animals or ingestion of unpasteurized milk or close contact with their secretion. Brucellosis vaccine is meant for cattle, sheep and goats. Currently, there is no vaccine available for humans. Vaccination works by producing an immune response that increases the animal's resistance to the diseases and is important to control, manage and eliminate brucellosis.

MARKET DYNAMICS

Growing livestock production and the threat of animal-borne infectious diseases are driving the growth of the market. With continuous growth and transformation of the livestock sector offer substantial challenges associated with food security and human nutrition. Demand for livestock products is growing influenced by increasing consumption of milk, meat, and eggs. Globally, brucellosis is considered as the most common zoonotic disease, with more than 500,000 cases recorded annually. Growth of the market is backed by a vaccination programme. On the other hand, there are many regions where effective diagnosis or treatment is not available or where programmes for the detection and prevention of the infection in humans and animals are not adequately carried out. Such regions need co-ordination and collaboration between veterinary and health sectors of government to help prevent and control brucellosis.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Brucellosis Vaccines. The growth and trends of Brucellosis Vaccines industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Brucellosis Vaccines market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

  • Subunit Vaccines (Recombinant Vaccines, Conjugate Vaccines, Toxoid Vaccines)
  • Inactivated
  • Live Attenuated
  • mRNA Aaccines
  • Viral Vector Vaccines

By Route of Administration

  • Oral
  • Parenteral
  • Nasal

By Disease Indication

  • Viral Diseases (Hepatitis, Influenza, HPV, MMR, Rotavirus, Herpes Zoster, Covid-19, Others)
  • Bacterial Vaccines (Meningococcal Diseases, Pneumococcal Diseases, DPT, Others)
  • Cancer Vaccines
  • Allergy Vaccines

By Age

  • Pediatric
  • Adult

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Brucellosis Vaccines market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Brucellosis Vaccines market include Merck & Co. Inc., Laboratories Tornel, Hester Biosciences Limited, Ceva, CZ Vaccines. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. BRUCELLOSIS VACCINES - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Type
    • 3.7.2 Market Attractiveness Analysis By Route of Administration
    • 3.7.3 Market Attractiveness Analysis By Disease Indication
    • 3.7.4 Market Attractiveness Analysis By Age
    • 3.7.5 Market Attractiveness Analysis By Distribution Channel
    • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY TYPE

  • 5.1. Overview By Type
  • 5.2. Historical and Forecast Data Analysis By Type
  • 5.3. Subunit Vaccines (Recombinant Vaccines, Conjugate Vaccines, Toxoid Vaccines) Historic and Forecast Sales By Regions
  • 5.4. Inactivated Historic and Forecast Sales By Regions
  • 5.5. Live Attenuated Historic and Forecast Sales By Regions
  • 5.6. mRNA Aaccines Historic and Forecast Sales By Regions
  • 5.7. Viral Vector Vaccines Historic and Forecast Sales By Regions

6. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 6.1. Overview By Route of Administration
  • 6.2. Historical and Forecast Data Analysis By Route of Administration
  • 6.3. Oral Historic and Forecast Sales By Regions
  • 6.4. Parenteral Historic and Forecast Sales By Regions
  • 6.5. Nasal Historic and Forecast Sales By Regions

7. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY DISEASE INDICATION

  • 7.1. Overview By Disease Indication
  • 7.2. Historical and Forecast Data Analysis By Disease Indication
  • 7.3. Viral Diseases (Hepatitis, Influenza, HPV, MMR, Rotavirus, Herpes Zoster, Covid-19, Others) Historic and Forecast Sales By Regions
  • 7.4. Bacterial Vaccines (Meningococcal Diseases, Pneumococcal Diseases, DPT, Others) Historic and Forecast Sales By Regions
  • 7.5. Cancer Vaccines Historic and Forecast Sales By Regions
  • 7.6. Allergy Vaccines Historic and Forecast Sales By Regions

8. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY AGE

  • 8.1. Overview By Age
  • 8.2. Historical and Forecast Data Analysis By Age
  • 8.3. Pediatric Historic and Forecast Sales By Regions
  • 8.4. Adult Historic and Forecast Sales By Regions

9. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 9.1. Overview By Distribution Channel
  • 9.2. Historical and Forecast Data Analysis By Distribution Channel
  • 9.3. Hospital & Retail Pharmacies Historic and Forecast Sales By Regions
  • 9.4. Government Suppliers Historic and Forecast Sales By Regions
  • 9.5. Others Historic and Forecast Sales By Regions

10. GLOBAL BRUCELLOSIS VACCINES MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2 North America By Segment Sales Analysis
    • 10.3.3 North America By Country Sales Analysis
    • 10.3.4 United States Sales Analysis
    • 10.3.5 Canada Sales Analysis
    • 10.3.6 Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2 Europe By Segment Sales Analysis
    • 10.4.3 Europe By Country Sales Analysis
    • 10.4.4 United Kingdom Sales Analysis
    • 10.4.5 France Sales Analysis
    • 10.4.6 Germany Sales Analysis
    • 10.4.7 Italy Sales Analysis
    • 10.4.8 Russia Sales Analysis
    • 10.4.9 Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2 Asia Pacific By Segment Sales Analysis
    • 10.5.3 Asia Pacific By Country Sales Analysis
    • 10.5.4 China Sales Analysis
    • 10.5.5 India Sales Analysis
    • 10.5.6 Japan Sales Analysis
    • 10.5.7 South Korea Sales Analysis
    • 10.5.8 Australia Sales Analysis
    • 10.5.9 South East Asia Sales Analysis
    • 10.5.10 Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2 Latin America By Segment Sales Analysis
    • 10.6.3 Latin America By Country Sales Analysis
    • 10.6.4 Brazil Sales Analysis
    • 10.6.5 Argentina Sales Analysis
    • 10.6.6 Peru Sales Analysis
    • 10.6.7 Chile Sales Analysis
    • 10.6.8 Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2 Middle East & Africa By Segment Sales Analysis
    • 10.7.3 Middle East & Africa By Country Sales Analysis
    • 10.7.4 Saudi Arabia Sales Analysis
    • 10.7.5 UAE Sales Analysis
    • 10.7.6 Israel Sales Analysis
    • 10.7.7 South Africa Sales Analysis
    • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE BRUCELLOSIS VACCINES COMPANIES

  • 11.1. Brucellosis Vaccines Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12. COMPANY PROFILES OF BRUCELLOSIS VACCINES INDUSTRY

  • 12.1. Top Companies Market Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Merck & Co. Inc.
    • 12.3.1 Company Overview
    • 12.3.2 Company Revenue
    • 12.3.3 Products
    • 12.3.4 Recent Developments
  • 12.4. Laboratories Tornel
    • 12.4.1 Company Overview
    • 12.4.2 Company Revenue
    • 12.4.3 Products
    • 12.4.4 Recent Developments
  • 12.5. Hester Biosciences Limited
    • 12.5.1 Company Overview
    • 12.5.2 Company Revenue
    • 12.5.3 Products
    • 12.5.4 Recent Developments
  • 12.6. Ceva
    • 12.6.1 Company Overview
    • 12.6.2 Company Revenue
    • 12.6.3 Products
    • 12.6.4 Recent Developments
  • 12.7. CZ Vaccines
    • 12.7.1 Company Overview
    • 12.7.2 Company Revenue
    • 12.7.3 Products
    • 12.7.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies